Tuesday, 19 October 2021


Menarini to commercialize Japanese drug in Singapore, Malaysia, and the Philippines

23 August 2021 | News

New drug TARLIGE helps in the treatment of peripheral neuropathic pain (PNP), including diabetic PNP and post-herpetic neuralgia

Photo Credit: Freepik

Photo Credit: Freepik

Singapore-based Menarini Asia-Pacific Holdings, a part of the leading Italian global biopharmaceutical company Menarini Group, has signed a multi-year exclusive licensing agreement to assume the registration, sales, marketing, and distribution of the orally administered gabapentinoid, mirogabalin (brand name; TARLIGE®), in the PhilippinesMalaysia and Singapore.

TARLIGE® was developed and is currently marketed in Japan by Daiichi Sankyo Company, Limited and is indicated for the treatment of peripheral neuropathic pain (PNP), including diabetic PNP and post-herpetic neuralgia. The drug binds to and modulates the alpha 2 delta-1 subunit of the voltage-gated calcium channels widely found in the nervous system in areas that mediate pain transmission and processing.

Neuropathic pain, which refers to pain caused by a lesion or disease of the somatosensory nervous system, has been shown to be prevalent in the general population by as much as 7 to 8 percent. Patients with neuropathic pain are more susceptible to high pain intensity with more comorbidities, such as depression panic/anxiety disorder, and sleep disorders.

"The Menarini Group already has an on-going global partnership with Daiichi Sankyo and the partnership on TARLIGE® is another important milestone for us. This is a strategic move to complement our established portfolio of pain products that cover acute to chronic and cancer pain. Menarini Asia-Pacific is committed to helping alleviate pain and delivering treatment solutions to address the unmet needs of patients in this region," said Maurizio Luongo, CEO of Menarini Asia-Pacific.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account